NA
ONCY

NewEdge Advisors’s Oncolytics Biotech ONCY Stock Holding History

NewEdge Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60 Buy
+63
New +$58 ﹤0.01% 4153

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NewEdge Advisors's ONCY Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Oncolytics Biotech (ONCY) in Q2 2026: 63 shares worth $60. The stake represents ﹤0.01% of the portfolio and ranks #4153 among its holdings.

55 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • NewEdge Advisors held 63 shares of Oncolytics Biotech worth $60 as of Q2 2026.
  • Oncolytics Biotech was a new NewEdge Advisors position in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4153 holding.
  • 55 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.